Insmed Incorporated

NASDAQ:INSM

Biotechnology

Healthcare
$119.80 -2.77%

-$2.73 today

Market cap
$26.28B
Beta
0.77
P/E (TTM)
-17.4
EPS (TTM)
-$5.49
52W Low $90.39High $212.75

Volume 1.94M

Average 3.31M

INSM Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Insmed IncorporatedNASDAQ: INSM

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 84.2%

Gross margin was 84.2% in Q2 FY2026, up 10.3 pp from a year earlier. On a trailing-twelve-month basis it was 83.3%, up 7.6 pp year over year. Over 3 fiscal years it widened by 1.9 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
84.2%+0.4 pp QoQ
Last fiscal yearDec 2025
79.4%+3.0 pp YoY
LTMJun 2026
83.3%+7.6 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+10.3 pp——
1 year+3.0 pp——
3 years+1.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
79.4%
Year-over-year change
+3.0pp

Gross Margin vs competitors

How INSM compares with its peers on the latest reported figures

  • INSM's LTM Jun 2026 gross margin of 83.3% is the 3rd highest of the 4 companies compared; the peer median is 86.1%.
  • Its year-over-year change of +7.6 pp is the 3rd highest of 4, against a peer median of +22.1 pp.
  • Over three fiscal years its change of +1.9 pp compares with a peer median of +9.6 pp.
INSM Competitors Peer median
Gross Margin for INSM and competitors
Company Period LTM level YoY 3-year change
LQDALiquidia CorporationLTM Jun 202692.5% +22.1 pp+9.6 pp
UTHRUnited Therapeutics CorporationLTM Jun 202686.1% -2.8 pp-4.5 pp
INSMInsmed IncorporatedLTM Jun 202683.3% +7.6 pp+1.9 pp
TBPHTheravance Biopharma, Inc.LTM Mar 202680.4% +41.9 pp+118.3 pp
AVLNAvalyn Pharma Inc. Common Stock—— ——
Peer median (excluding INSM) 86.1%+22.1 pp+9.6 pp

Competitors are the stored peer set for INSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue188.46M245.36M305.21M363.71M606.42M
Cost of Revenue44.15M55.13M65.57M85.74M124.88M
Gross Profit144.31M190.23M239.64M277.97M481.55M
Gross Margin76.6%77.5%78.5%76.4%79.4%
Research & Development272.74M397.52M571.01M598.37M771.09M
Selling, General & Admin234.27M265.78M344.5M461.12M701.17M
Operating Expenses519.4M647.55M949.26M1.16B1.66B
Depreciation & Amortization14.18M10.33M10.58M11.01M16.45M
EBITDA(383.65M)(447.37M)(660.18M)(818.79M)(1.17B)
EBITDA Margin-203.6%-182.3%-216.3%-225.1%-193.2%
Operating Income(375.09M)(457.32M)(709.63M)(878.25M)(1.18B)
Operating Margin-199.0%-186.4%-232.5%-241.5%-194.0%
Interest Income174K11.08M42.13M53.31M60.66M
Interest Expense40.47M26.45M81.69M84.91M83.8M
Other Income / Expenses(61.32M)(22.83M)(37.39M)(31.81M)(95.02M)
Income Before Tax(436.41M)(480.15M)(747.01M)(910.07M)(1.27B)
Pre-Tax Margin-231.6%-195.7%-244.8%-250.2%-209.7%
Income Tax Expense(1.76M)1.38M2.56M3.71M5.03M
Net Income(434.65M)(481.53M)(749.57M)(913.77M)(1.28B)
Net Margin-230.6%-196.3%-245.6%-251.2%-210.5%
EPS (Basic)(3.88)(3.91)(5.34)(5.57)(6.41)
EPS (Diluted)(3.88)(3.91)(5.34)(5.57)(6.41)
Weighted Avg Shares112.11M123.04M140.43M164.04M213.64M
Weighted Avg Shares (Diluted)112.11M123.04M140.43M164.04M213.64M

Insmed Incorporated

NASDAQ:INSM

Intrinsic Alpha fair value

Locked

Current Price

$119.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.